- Home
- ACRS vs BRY Comparison
ACRS vs BRY Comparison
Compare ACRS & BRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- BRY
- Stock Information
- Founded
- ACRS 2012
- BRY 1909
- Country
- ACRS United States
- BRY United States
- Employees
- ACRS N/A
- BRY N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- BRY Oil & Gas Production
- Sector
- ACRS Health Care
- BRY Energy
- Exchange
- ACRS Nasdaq
- BRY Nasdaq
- Market Cap
- ACRS 165.7M
- BRY 186.1M
- IPO Year
- ACRS 2015
- BRY N/A
- Fundamental
- Price
- ACRS $1.45
- BRY $3.30
- Analyst Decision
- ACRS Strong Buy
- BRY Buy
- Analyst Count
- ACRS 8
- BRY 2
- Target Price
- ACRS $9.71
- BRY $5.00
- AVG Volume (30 Days)
- ACRS 780.3K
- BRY 1.3M
- Earning Date
- ACRS 08-06-2025
- BRY 08-08-2025
- Dividend Yield
- ACRS N/A
- BRY 3.64%
- EPS Growth
- ACRS N/A
- BRY N/A
- EPS
- ACRS N/A
- BRY N/A
- Revenue
- ACRS $17,777,000.00
- BRY $753,737,000.00
- Revenue This Year
- ACRS N/A
- BRY N/A
- Revenue Next Year
- ACRS $11.77
- BRY $0.96
- P/E Ratio
- ACRS N/A
- BRY N/A
- Revenue Growth
- ACRS N/A
- BRY N/A
- 52 Week Low
- ACRS $1.05
- BRY $2.11
- 52 Week High
- ACRS $5.17
- BRY $7.02
- Technical
- Relative Strength Index (RSI)
- ACRS 51.96
- BRY 70.73
- Support Level
- ACRS $1.37
- BRY $2.99
- Resistance Level
- ACRS $1.59
- BRY $3.39
- Average True Range (ATR)
- ACRS 0.10
- BRY 0.16
- MACD
- ACRS -0.01
- BRY 0.08
- Stochastic Oscillator
- ACRS 28.57
- BRY 90.91
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About BRY Berry Corporation (bry)
Berry Corp (bry) is a western United States independent upstream energy company with a focus on the conventional, long-lived oil reserves in the San Joaquin basin of California. Its operating segments includes Exploration and Production (E&P) and Well Servicing and Abandonment. The company generates maximum revenue from the Exploration and Production (E&P) segment.